Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis

Psoriasis is a chronic, inflammatory skin disease that produces red, scaly patches. It negatively affects patients’ quality of life and is associated with several other conditions, including cardiovascular disease, hypertension, hyperlipidaemia, diabetes and depression. Approximately 100 million people worldwide have psoriasis. Risankizumab is approved for the treatment of moderate‐to‐severe plaque psoriasis in more than 70 countries. In this study, with authors from around the world, the study looked at the long‐term safety of risankizumab using data from 17 different clinical trials of risankizumab. These studies have been conducted in a number of countries. The study gathered together all the data from these different studies, and in total, they included information about more than 3000 patients. This way, the study surveyed over 7900 patient‐years of exposure to risankizumab. In addition, the study looked at whether this treatment increased adverse events such as respiratory infections, injection‐site reactions, and cancers. Again, the results were reassuring—these findings of its safety support risankizumab as a long‐term treatment option for patients with moderate‐to‐severe psoriasis.